Mesoblast's blood cancers stem cell therapy moves closer to market
This article was originally published in Clinica
Executive Summary
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.